Buchumschlag

Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access study

Following positive results from the Phase III CHEST-1 study in patients with inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH), the Phase IIIb CTEPH early access study (EAS) was designed to assess the safety and tolerability of riociguat in real-world clinical...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: McLaughlin, Vallerie V. (VerfasserIn) , Grünig, Ekkehard (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 28 December 2017
In: BMC pulmonary medicine
Year: 2017, Jahrgang: 17
ISSN:1471-2466
DOI:10.1186/s12890-017-0563-7
Online-Zugang:Verlag, Volltext: http://dx.doi.org/10.1186/s12890-017-0563-7
Verlag, Volltext: https://doi.org/10.1186/s12890-017-0563-7
Volltext
Verfasserangaben:Vallerie V. McLaughlin, Pavel Jansa, Jens E. Nielsen-Kudsk, Michael Halank, Gérald Simonneau, Ekkehard Grünig, Silvia Ulrich, Stephan Rosenkranz, Miguel A. Gómez Sánchez, Tomás Pulido, Joanna Pepke-Zaba, Joan Albert Barberá, Marius M. Hoeper, Jean-Luc Vachiéry, Irene Lang, Francine Carvalho, Christian Meier, Katharina Mueller, Sylvia Nikkho and Andrea M. D’Armini
Beschreibung
Zusammenfassung:Following positive results from the Phase III CHEST-1 study in patients with inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH), the Phase IIIb CTEPH early access study (EAS) was designed to assess the safety and tolerability of riociguat in real-world clinical practice, as well as to provide patients with early access to riociguat before launch. Riociguat is approved for the treatment of inoperable and persistent/recurrent CTEPH.
Beschreibung:Gesehen am 16.11.2018
Beschreibung:Online Resource
ISSN:1471-2466
DOI:10.1186/s12890-017-0563-7

Ähnliche Einträge